Version history

1 version on record. Newest first; the live version sits at the top with a live indicator.

  1. Live
    4/26/2026, 3:49:09 PM
    Content snapshot
    {
      "session_id": "hyp-debate-664901bf-26d17faf82",
      "round_number": 3,
      "agent_persona": "persona-Synthesizer",
      "agent_backend": "codex",
      "action": "synthesize",
      "content": "Synthesizer summary for 'plasma GFAP separates causal from compensatory states in: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration':\nConsensus: both sides agree the hypothesis is specific enough to test and that plasma GFAP gives the Agora a concrete measurement or perturbation axis. The debate also agrees that the existing evidence is more supportive of plausibility than of demonstrated causality.\n\nDissent: the Theorist treats the gap-debate evidence and cited mechanisms as sufficient to prioritize experiments now; the Skeptic requires claim-level citation validation and temporal perturbation data before promotion into the world model.\n\nConfidence update: score_before=0.738; score_after=0.731. The debate modestly decreases because the hypothesis is actionable and high-impact, but uncertainty remains around causal direction and citation specificity. Recommended next step: run a targeted evidence-validation pass and design the longitudinal perturbation assay named in the hypothesis description.",
      "hypotheses_referenced": "h-gap-5c6cec3e-m2",
      "evidence_cited": "[\"four_round_gap_debate [four_round_gap_debate]\", \"Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity. [32388602]\", \"The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice. [40468412]\", \"Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration. [39441380]\"]",
      "confidence": 0.731,
      "argument": "Synthesizer summary for 'plasma GFAP separates causal from compensatory states in: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration':\nConsensus: both sides agree the hypothesis is specific enough to test and that plasma GFAP gives the Agora a concrete measurement or perturbation axis. The debate also agrees that the existing evidence is more supportive of plausibility than of demonstrated causality.\n\nDissent: the Theorist treats the gap-debate evidence and cited mechanisms as sufficient to prioritize experiments now; the Skeptic requires claim-level citation validation and temporal perturbation data before promotion into the world model.\n\nConfidence update: score_before=0.738; score_after=0.731. The debate modestly decreases because the hypothesis is actionable and high-impact, but uncertainty remains around causal direction and citation specificity. Recommended next step: run a targeted evidence-validation pass and design the longitudinal perturbation assay named in the hypothesis description.",
      "evidence": "[\"four_round_gap_debate [four_round_gap_debate]\", \"Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity. [32388602]\", \"The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice. [40468412]\", \"Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration. [39441380]\"]"
    }